IPO - ARS Pharmaceuticals, Inc.

Form Type: S-3ASR

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000119312525018480

Filing Summary: ARS Pharmaceuticals, Inc. filed a registration statement under Form S-3 on January 31, 2025. The document highlights that the company is focused on the commercialization and development of its needle-free epinephrine product, neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy, which has received FDA and European Commission approval, represents the first new delivery method for epinephrine in over 35 years. The document clarifies that ARS was incorporated in Delaware in January 2016 and underwent a name change in November 2022. It outlines the plans to offer an aggregate of up to $200 million worth of common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. Additionally, the prospectus discusses the issuance of various securities, including common stock, preferred stock, debt securities, and warrants, specifying terms that will be detailed in subsequent prospectus supplements. The company has a focus on using the proceeds from these offerings for general corporate purposes, including the commercialization activities related to neffy and research and development costs.

Document Link: View Document